Liquid biopsy devices analyze blood samples to detect cancer-related biomarkers, such as circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs). These devices offer a non-invasive alternative to traditional tissue biopsies, enabling continuous monitoring of cancer progression and response to treatment. Liquid biopsies can provide early insights into genetic mutations and potential drug resistance.
